U.S. markets open in 1 hour 29 minutes

Diffusion Pharmaceuticals Inc. (DFFN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.12+0.22 (+3.19%)
At close: 04:00PM EDT
7.12 0.00 (0.00%)
After hours: 07:48PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close6.90
Bid6.90 x 1000
Ask7.40 x 1100
Day's Range6.80 - 7.40
52 Week Range5.10 - 31.50
Avg. Volume30,425
Market Cap14.519M
Beta (5Y Monthly)1.57
PE Ratio (TTM)N/A
EPS (TTM)-11.70
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for DFFN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Diffusion Pharmaceuticals Inc.
    Daily – Vickers Top Buyers & Sellers for 01/11/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    7 months agoArgus Research
View more
  • Zacks Small Cap Research

    DFFN: Phase 2 GBM Trial to Initiate 2H22…

    By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Phase 2 GBM Trial to Initiate in 2H22 In July 2022, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced that the company had aligned with the U.S. Food and Drug Administration (FDA) on the design of an open label, dose escalation, Phase 2 safety and efficacy study (Study 200-208) of its lead development

  • GlobeNewswire

    Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

    • Aligned with FDA on Design of Phase 2 GBM Trial of TSC; Initiation Expected by End of 2022• Reported Positive Effects in TSC Altitude Trial• Ended Quarter with $28.5 million in Cash, Cash Equivalents and Marketable Securities• Expected Cash Runway into First Quarter of 2024 CHARLOTTESVILLE, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that may enhance the body’s abilit

  • GlobeNewswire

    Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

    Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”) patientsCompany to evaluate effects of TSC on tumor oxygenation using an innovative positron emission tomography (“PET”) hypoxia imaging methodology with data expected within one year of study initiationDiffusion previously obtained Orphan Drug Designation for use of TSC in conjunction with radiotherapy for